Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2006; 12(35): 5692-5698
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Table 2 Comparison of response of hepatitis C in both groups
| Variable | Group A(PEG-IFN+RBV)n = 38 | Group B(IFN+RBV)n = 35 | P |
| After 48 wk | |||
| Responders | 29 (76.3) | 14 (40.0) | < 0.002 |
| Non-responders | 9 (23.7) | 21 (60.0) | |
| After 72 wk | |||
| Among responders | |||
| Sustained response | 25 (86.2) | 9 (64.3) | 0.124 |
| Relapser | 4 (13.8) | 5 (35.7) | |
- Citation: Derbala M, Kaabi SA, Dweik NE, Pasic F, Butt M, Yakoob R, Al-Marri A, Amer A, Morad N, Bener A. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12(35): 5692-5698
- URL: https://www.wjgnet.com/1007-9327/full/v12/i35/5692.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i35.5692